Healthcare Analysts discuss regulatory landscape for AAV-based gene therapies (relevant companies (SLDB, TSHA, BNTC, SRPT, QURE, NTLA, CRSP, PRME) on an Analyst/industry conference calll on November 21.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Strategic Advancements and Growth Potential: Solid Biosciences’ Buy Rating Validated by Key Partnerships and Regulatory Progress
- Solid Biosciences announces licensing agreement with Andelyn Biosciences
- Solid Biosciences announces SGT-003 granted an Innovation Passport under ILAP
- Solid Biosciences price target lowered to $11 from $13 at JPMorgan
- Solid Biosciences price target lowered to $14 from $16 at Citi